Layout of the Eco-industrial Chain
CRO (Teddy Lab)
As a joint venture between DIAN DIAGNOSTICS and Tigermed, the Teddy Lab focuses on providing international standard laboratory services in China. The lab has extensive project experience in the fields of oncology, immunology, endocrinology, cardiovasology, hematology, lemology and COPD, and has provided complex, professional laboratory solutions for more than 350 phase I-IV clinical drug trials, offering a one-stop solution for central CRO laboratory services.

Health Management
Medical Mall
In 2016, three listed companies - DIAN DIAGNOSTICS, Jiebai Group and Baida Group - jointly established the Medical Mall, the first integrated health care and retail business mall in China.
DIAN Healthcare
DIAN Healthcare established a one-stop health management service agency, covering everything from in-depth physical examination to precision medicine; from chronic disease treatment to sub-health management. Physical examination- business as its entry point, health management as its core, specialty development as its means and medical service as its support.
DIAN FORENSICS is a third-party forensic institute based on an independent laboratory platform. Eight forensics chain institutions has been built in China. Development strategies for independent forensic services and products were established and, ten key services and products were created.
Integrated Medical Cold Chain Warehousing
Zhejiang DIAN Shenhai Cold-Chain Logistics Co., Ltd. specializes in domestic and international cold chain storage, cold chain distribution, sales and technical services of medical devices; medicines; diagnostic, biological and blood products. The company is committed to customizing one-stop cold-chain storage and distribution solutions and providing personalized value-added services for customers in the fields of life science and biological engineering.
ZJH FUND is the first private equity industry fund jointly initiated by a number of listed companies in China's healthcare industry. It focuses on investments in great health initiatives, with a total target fund of RMB 10 billion. The first phase investment of RMB 1 billion has been completed, with two projects now listed on stock market and one in the final stage of IPO.